Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Farletuzumab ecteribulin |
| Trade Name | |
| Synonyms | MORAb 202|MORAb202|MORAb-202 |
| Drug Descriptions |
Farletuzumab ecteribulin (MORAb-202) is an anti-folate receptor alpha (FRA) antibody (farletuzumab) in conjugation with eribulin, which may lead to cytotoxic killing of FRA-positive tumors (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B115, PMID: 30262588). |
| DrugClasses | FOLR1-targeted Therapy 24 |
| CAS Registry Number | 2407465-18-1 |
| NCIT ID | C173946 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Dexamethasone + Farletuzumab ecteribulin | Dexamethasone Farletuzumab ecteribulin | 0 | 1 |
| Farletuzumab ecteribulin | Farletuzumab ecteribulin | 0 | 3 |
| Farletuzumab ecteribulin + Lenvatinib | Farletuzumab ecteribulin Lenvatinib | 0 | 1 |
| Farletuzumab ecteribulin + Prednisolone | Farletuzumab ecteribulin Prednisolone | 0 | 1 |
| Farletuzumab ecteribulin + Prednisone | Farletuzumab ecteribulin Prednisone | 0 | 1 |